Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

STING: a master regulator in the cancer-immunity cycle
Yuanyuan Zhu, Xiang An, Xiao Zhang, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 296

Showing 26-50 of 296 citing articles:

DNA Damage Response and Immune Defense
Claudia Nastasi, Laura Mannarino, Maurizio D’Incalci
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7504-7504
Open Access | Times Cited: 98
Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration
Mohamed Wehbe, Lihong Wang-Bishop, Kyle W. Becker, et al.
Journal of Controlled Release (2020) Vol. 330, pp. 1118-1129
Open Access | Times Cited: 92
Type I and II Interferons in the Anti-Tumor Immune Response
Sarah E. Fenton, Diana Saleiro, Leonidas C. Platanias
Cancers (2021) Vol. 13, Iss. 5, pp. 1037-1037
Open Access | Times Cited: 88
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock
Trends in cancer (2020) Vol. 7, Iss. 1, pp. 15-28
Open Access | Times Cited: 81
Biomarkers of Radiotherapy-Induced Immunogenic Cell Death
Rianne D.W. Vaes, Lizza E.L. Hendriks, Marc Vooijs, et al.
Cells (2021) Vol. 10, Iss. 4, pp. 930-930
Open Access | Times Cited: 79
Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer
Zhou Li, Qiuli Xu, Litang Huang, et al.
Cancer Letters (2020) Vol. 500, pp. 163-171
Closed Access | Times Cited: 78
Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist
Shanshan Gou, Wenwen Liu, Shuai Wang, et al.
Nano Letters (2021) Vol. 21, Iss. 23, pp. 9939-9950
Closed Access | Times Cited: 70
EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion
Antonio Marzio, Emma Kurz, Jennifer M. Sahni, et al.
Cell (2021) Vol. 185, Iss. 1, pp. 169-183.e19
Open Access | Times Cited: 70
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
Seung Joon Lee, Hannah Yang, Woo Ram Kim, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002195-e002195
Open Access | Times Cited: 68
Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity
Kathleen M. McAndrews, Sara P.Y., Valerie S. LeBleu, et al.
Journal of Biological Chemistry (2021) Vol. 296, pp. 100523-100523
Open Access | Times Cited: 61
The Evolution of STING Signaling and Its Involvement in Cancer
Nimi Vashi, Samuel F. Bakhoum
Trends in Biochemical Sciences (2021) Vol. 46, Iss. 6, pp. 446-460
Open Access | Times Cited: 59
STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
Elvire Pons‐Tostivint, Alexandre Lugat, Jean-François Fontenau, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3129-3129
Open Access | Times Cited: 56
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer
Alok Kumar Singh, Monali Praharaj, Kara A. Lombardo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 52
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models
Santiago Haase, Kaushik Banerjee, Anzar Mujeeb, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 22
Open Access | Times Cited: 50
A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy
Taokun Luo, Geoffrey T. Nash, Xiaomin Jiang, et al.
Advanced Materials (2022) Vol. 34, Iss. 39
Open Access | Times Cited: 49
Encapsulation of Platinum Prodrugs into PC7A Polymeric Nanoparticles Combined with Immune Checkpoint Inhibitors for Therapeutically Enhanced Multimodal Chemotherapy and Immunotherapy by Activation of the STING Pathway
Xiangjie Gao, Guanxiong Lei, Bin Wang, et al.
Advanced Science (2022) Vol. 10, Iss. 4
Open Access | Times Cited: 46
Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
Lindsey Carlsen, Kelsey E. Huntington, Wafik S. El‐Deiry
Cancers (2022) Vol. 14, Iss. 4, pp. 1028-1028
Open Access | Times Cited: 41
Leukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndrome
Julia Stokes, Rebecca Bornstein, Katerina James, et al.
JCI Insight (2022) Vol. 7, Iss. 5
Open Access | Times Cited: 40
Metal‐Cyclic Dinucleotide Nanomodulator‐Stimulated STING Signaling for Strengthened Radioimmunotherapy of Large Tumor
Duo Wang, Tianqi Nie, Cuiqing Huang, et al.
Small (2022) Vol. 18, Iss. 41
Closed Access | Times Cited: 40
Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy
Ke-Wang Luo, Ning Li, Wei Ye, et al.
Molecules (2022) Vol. 27, Iss. 14, pp. 4638-4638
Open Access | Times Cited: 39
Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
Cuiqing Huang, Ni Shao, Yanyu Huang, et al.
Materials Today Bio (2023) Vol. 23, pp. 100839-100839
Open Access | Times Cited: 35
cGAS-STING pathway as a potential trigger of immunosenescence and inflammaging
Carine Raquel Richter Schmitz, Rafael Moura Maurmann, Fátima Theresinha Costa Rodrigues Guma, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 34
Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy
Yongjuan Li, Xinyan Li, Jinmeng Yi, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 19
Closed Access | Times Cited: 31
S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
Huihuang Li, Jinbo Chen, Zhenghao Li, et al.
Advanced Science (2023) Vol. 10, Iss. 25
Open Access | Times Cited: 31
Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy
Hao Yang, Zhong-Hao Ji, Hengzong Zhou, et al.
MedComm (2023) Vol. 4, Iss. 4
Open Access | Times Cited: 30

Scroll to top